Hari Kiran Chereddi, MD & CEO of HRV Pharma and NHG Pharma, shares strategic insights on India's readiness and the fundamental changes required to capitalize on this high-value market opportunity
Yet not one of them went through long-term trials to determine whether or not they would be safe for a lifetime
[DOI] [PMC free article] [PubMed] [Google Scholar] 150.Olagnier D., Brandtoft A.M., Gunderstofte C., Villadsen N.L., Krapp C., Thielke A.L., Laustsen A., Peri S., Hansen A.L., Bonefeld L., et al
n = 5 biological replicates
Bladder tumors exhibit increased levels of apoptosis markers (p53, p21, Bax, and Annexin)
Your doctor will start the medication at 0.25 mg weekly, increasing it to the 0.5 mg dose after four weeks, followed by 1 mg and 2 mg after four more weeks of each dose, depending on your tolerance and needs